Now showing items 7-13 of 13

    • Decline in antigenicity of tumour markers by storage time using pathology sections cut from tissue micro-arrays 

      Blows, Fiona M.; Ali, H. Raza; Dawson, Sarah-Jane; Le Quesne, John; Provenzano, Elena; Caldas, Carlos; Pharoah, Paul D. P. (Lippincott Williams & Wilkins/Wolters Kluwer Health, 2015-06-05)
      Sectioning a whole tissue microarrray (TMA block) and storing the sections maximises the number of sections obtained, but may impair the antigenicity of the stored sections. We have investigated the impact of TMA section ...
    • Familial relative risks for breast cancer by pathological subtype: a population-based cohort study 

      Mavaddat, Nasim; Pharoah, Paul D. P.; Blows, Fiona; Driver, Kristy E.; Provenzano, Elena; Thompson, Deborah J.; MacInnis, Robert J. et al. (2010-02-10)
      Abstract Introduction The risk of breast cancer to first degree relatives of breast cancer patients is approximately twice that of the general population. Breast cancer, however, is a heterogeneous disease and it is plausible ...
    • Multifocal clonal evolution characterized using circulating tumor DNA in a case of metastatic breast cancer 

      Murtaza, Muhammed; Dawson, Sarah-­Jane; Pogrebniak, Katherine; Rueda, Oscar M.; Provenzano, Elena; Grant, John; Chin, Suet-Feung et al. (Nature Publishing Group, 2015-11-04)
      Circulating tumour DNA analysis can be used to track tumour burden and analyse cancer genomes non-invasively but the extent to which it represents metastatic heterogeneity is unknown. Here we follow a patient with metastatic ...
    • Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean? 

      Earl, Helena; Provenzano, Elena; Abraham, Jean; Dunn, Janet; Vallier, Anne-Laure; Gounaris, Ioannis; Hiller, Louise (2015-09-22)
      Abstract Background Neoadjuvant breast cancer trials are important for speeding up the introduction of new treatments for patients with early breast cancer and for the highly ...
    • Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium 

      Howat, William; Blows, Fiona; Provenzano, Elena; Brook, Mark; Morris, Lorna; Gazinska, Patrycja; Johnson, Nicola et al. (Wiley, 2014-12-04)
      Breast cancer risk factors and clinical outcomes vary by tumor marker expression. However, individual studies often lack the power required to assess these relationships, and large-scale analyses are limited by the need ...
    • Research data supporting "Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer" 

      Candido do Reis, Francisco J.; Lynn, Stuart; Ali, H. Raza; Eccles, Diana; Hanby, Andrew; Provenzano, Elena; Caldas, Carlos et al. (2015-05-08)
    • The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes 

      Pereira, Bernard; Chin, Suet-Feung; Rueda, Oscar M.; Vollan, Hans-Kristian Moen; Provenzano, Elena; Bardwell, Helen A.; Pugh, Michelle et al. (Nature Publishing Group, 2016-05-10)
      The genomic landscape of breast cancer is complex, and inter- and intra-tumour heterogeneity are important challenges in treating the disease. In this study, we sequence 173 genes in 2,433 primary breast tumours that have ...